Development of Novel Schiff Base–Tyrosine Kinase Inhibitor Conjugates that Enhance the Effects of ALA-PDT
Anticancer Research · 2026-08 · 46 (8) · 4689-4698
DOI: 10.21873/anticanres.18325 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, online erschienen am 29.07.2026. Verfasst von Yusei Shinohara und 4 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Technology, Industrial and Social Science, Tokushima University, Tokushima, Japan. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Photochemotherapy, Aminolevulinic Acid, Photosensitizing Agents.
Abstract (Originalsprache)
Background/Aim: Photodynamic therapy (PDT) using 5-aminolevulinic acid (ALA) is a widely accepted and minimally invasive treatment for various cancers. The Schiff base derivative N-3′,5′-dichloro-2′-hydroxybenzylidene-2-chloro-4-nitroaniline (TX-816) markedly enhances the efficacy of ALA-based PDT (ALA-PDT) by promoting intracellular accumulation of protoporphyrin IX (PpIX). However, TX-816 is unstable in aqueous solutions and rapidly hydrolyzes into the active agent 3, 5-dichlorosalicylaldehyde (DCSA) and 2-chloro-4-nitroaniline, thereby complicating its clinical application. Materials and Methods: We synthesized UTX-144 (a dasatinib derivative) and UTX-148 (a gefitinib derivative) by conjugating the tyrosine-kinase inhibitors dasatinib or gefitinib with DCSA via a Schiff base. These novel ALA-PDT sensitizers conjugate tyrosine kinase inhibitors (TKIs) that target ATP-binding cassette subfamily G member 2 (ABCG2), a PpIX efflux transporter, with DCSA via a Schiff base.
Results
UTX-144 and UTX-148 showed strong ALA-PDT sensitization effects when used in combination with ALA, thereby increasing intracellular PpIX accumulation.
Conclusion
This study successfully developed the novel ALA-PDT sensitizers UTX-144 and UTX-148.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate School of Technology, Industrial and Social Science, Tokushima University, Tokushima, Japan.
- Department of Aging Science and Medicine, Graduate School of Medicine Kyoto University, Medical Innovation Center, Kyoto, Japan.
- Central Research Resource Branch, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
- Graduate School of Technology, Industrial and Social Science, Tokushima University, Tokushima, Japan; uto.yoshihiro@tokushima-u.ac.jp.
Zitieren
APA
Shinohara, Y., Abe, C., Endo, Y., Yamada, H., & Uto, Y. (2026). Development of Novel Schiff Base–Tyrosine Kinase Inhibitor Conjugates that Enhance the Effects of ALA-PDT. Anticancer Research, 46(8), 4689-4698. https://doi.org/10.21873/anticanres.18325
Vancouver
Shinohara Y, Abe C, Endo Y, Yamada H, Uto Y. Development of Novel Schiff Base–Tyrosine Kinase Inhibitor Conjugates that Enhance the Effects of ALA-PDT. Anticancer Research. 2026;46(8):4689-4698. doi:10.21873/anticanres.18325
BibTeX
@article{Shinohara2026,
author = {Shinohara, Yusei and Abe, Chiaki and Endo, Yoshio and Yamada, Hisatsugu and Uto, Yoshihiro},
title = {Development of Novel Schiff Base–Tyrosine Kinase Inhibitor Conjugates that Enhance the Effects of ALA-PDT},
journal = {Anticancer Research},
year = {2026},
volume = {46},
number = {8},
pages = {4689--4698},
doi = {10.21873/anticanres.18325}
}
EUVIMED